PTPN11 has been reported to participate in tumor immunotherapy resistance and has spawned several inhibitors, which can be applied in combination with anti-PD-1 and anti-PD-L1 therapies to improve immunotherapy efficacy [43–45]. Here, CD274 is linked to neoplasm.